Alignment Healthcare (ALHC)
(Delayed Data from NSDQ)
$8.59 USD
-0.08 (-0.92%)
Updated Aug 15, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Alignment Healthcare (ALHC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.79 | $12.00 | $7.00 | 13.97% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Alignment Healthcare comes to $9.79. The forecasts range from a low of $7.00 to a high of $12.00. The average price target represents an increase of 13.97% from the last closing price of $8.59.
Analyst Price Targets (12)
Broker Rating
Alignment Healthcare currently has an average brokerage recommendation (ABR) of 1.77 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.77 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy, representing 69.23% of all recommendations. A month ago, Strong Buy represented 69.23%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.77 | 1.77 | 1.77 | 1.77 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
7/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
5/8/2024 | Piper Sandler | Jessica E Tassan | Hold | Strong Buy |
5/5/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
5/3/2024 | Stephens | Scott Fidel | Hold | Hold |
3/6/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1/9/2024 | Raymond James | John W Ransom | Strong Buy | Strong Buy |
1/8/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
12/21/2023 | UBS | Kevin Caliendo | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.77 |
ABR (Last week) | 1.77 |
# of Recs in ABR | 13 |
Average Target Price | $9.79 |
LT Growth Rate | 29.30% |
Industry | Medical Services |
Industry Rank by ABR | 149 of 253 |
Current Quarter EPS Est: | -0.13 |